Showing results (101-110 of 117) with videos related to
Sort By:
Pageof 12
The American Journal of Cardiology|September 4, 2019
Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study)Björn Redfors, Shmuel Chen, Ori Ben-Yehuda, et al.JACC. Cardiovascular Interventions|January 8, 2016
Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?: "Window" Analysis From the ADAPT-DES Study (Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents)Ajay J Kirtane, Puja B Parikh, Thomas D Stuckey, et al.JACC. Cardiovascular Interventions|August 7, 2017
Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry StudyThomas D Stuckey, Ajay J Kirtane, Bruce R Brodie, et al.The American Journal of Cardiology|December 8, 2015
Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study)Mikkel M Schoos, George D Dangas, Roxana Mehran, et al.JACC. Cardiovascular Interventions|February 23, 2010
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)Gilles Montalescot, Stephen G Ellis, Mark A de Belder, et al.Circulation. Cardiovascular Interventions|February 15, 2017
Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents)Jennifer Yu, Roxana Mehran, Usman Baber, et al.The American Journal of Cardiology|March 5, 2004
Feasibility of endovascular cooling as an adjunct to primary percutaneous coronary intervention (results of the LOWTEMP pilot study)David E Kandzari, Alan Chu, Bruce R Brodie, et al.American Heart Journal|March 22, 2019
Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) studyMatthew T Finn, Björn Redfors, Dimitri Karmpaliotis, et al.The American Journal of Cardiology|April 13, 2016
Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents StudyGennaro Giustino, Ajay J Kirtane, Philippe Généreux, et al.Journal of the American Heart Association|December 24, 2022
On-Treatment Platelet Reactivity and Ischemic Outcomes in Patients With Diabetes Mellitus: Two-Year Results From ADAPT-DESBahira Shahim, Björn Redfors, Thomas D Stuckey, et al.Pageof 12